Primary open angle glaucoma or Ocular hypertension
Conditions
Interventions
Sponsors
Omatsu Kazunori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Aged 18 years or older at the time of Informed Consent (any gender) Have been diagnosed with primary open angle glaucoma or ocular hypertension Need to decrease intraocular pressure with ophthalmic solution in both eyes. Able to control intraocular pressure only by ophthalmic solution. Meet the other protocol-specified inclusion criteria
Exclusion criteria
Exclusion criteria: Have participated in other clinical trial and been administered investigational drug etc. or have a schedule of it during the period specified in protocol Have been conducted any treatment for glaucoma except for administration of ophthalmic solution during the period specified in protocol Have a history of ocular surgery/laser therapy to decrease intraocular pressure Have a history of intraocular surgery during the period specified in protocol, or a schedule of it during the study Have been conducted intraocular, sub-Tenon's, or subconjunctival injection of corticosteroid during the period specified in protocol Require to wear contact lens during the study Have active ocular disease other than primary open angle glaucoma or ocular hypertension Have severe visual field disorder Have abnormalities that interfere with measurement of intraocular pressure Have a history of corneal transplantation or corneal refractive surgery Have severe systemic illness Have a history of hypersensitivity or serious adverse reaction to any of the drugs used in the study Pregnant, lactating, or potentially pregnant. Unable to obtain a consent to practice adequate contraception during the study Unable to obtain a consent to practice adequate contraception and not to donate sperm during the study Have judged that it is inappropriate to participate in this study by investigator Meet the other protocol-specified exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in intraocular pressure from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy and Safety | — |
Contacts
Public Contactdivision Clinical
Senju Pharmaceutical Co., Ltd.
Outcome results
None listed